NDAs Steffen Thirstrup, Director NDA Regulatory Advisory Board and Bill Richardson, Pharmacovigilance & Risk Management Expert, have been invited to present at the DIA Workshop on Benefit-Risk Strategy in Hotel Grand Majestic Plaza, Prague 15-16 June.
Professor Thirstrup will chair and Dr Richardson will reflect a number of case studies that clarifies potential risk areas in Session 2: Implementing Benefit-Risk More Effectively.
The session will walk you through the do’s and don’ts of benefit-risk implementation. The essential elements of the session are: – What benefit-risk information to include in the clinical overview – Choosing the right qualitative or quantitative framework.
To read more about the event click here.